Mavenclad (cladribine tablets) from Merck KGaA, is now indicated for the treatment of adult patients with relapsing forms of Multiple Sclerosis (MS) with active disease as defined by… read more.
Lewy body disease, the second most common brain degenerative disease after Alzheimer’s disease, may be more common in middle-aged people than previously thought, Finnish researchers reported on March… read more.
28th EAHP Congress Highlights No fewer than 11 posters from Spanish pharmacists dealt with the use of monoclonal antibodies in the management of migraine. Anti-CGRP (calcitonin gene-related peptide)… read more.
In a study published in Nature Mental Health, scientists from China and the United States have found that individuals suffering from chronic musculoskeletal pain (CMP) may face a higher… read more.
Social activities such as interactions with others and participation in organised events can prevent cognitive decline in long-term care facility. Research from Amsterdam UMC, carried out among 3600… read more.
– Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, announced the FDA has… read more.
Researchers from an international phase 3 trial report that the standard Parkinson’s treatment levodopa delivered through an infusion pump rather than orally is safe and effective at reducing… read more.
Vanda Pharmaceuticals Inc. announced that on March 4, 2024, it received a Complete Response Letter (CRL) from the FDA as part of its ongoing review of Vanda’s supplemental… read more.
For middle-aged women plagued by migraines, or hot flashes and night sweats, another worry may linger in the backs of their minds: whether these experiences have set them… read more.
Biogen Inc. announced the European Commission (EC) has authorized Skyclarys (omaveloxolone) for the treatment of Friedreich’s ataxia (FA) in adults and adolescents aged 16 years and older …. read more.
Phosphodiesterase type 5 inhibitors (PDE5Is) used to treat erectile dysfunction might also reduce the risk of Alzheimer’s disease onset, researchers reported on Feb. 7, 2024 in Neurology. “Although… read more.
AbbVie has announced that Vyalev (foslevodopa/foscarbidopa solution) is now available for the treatment of motor fluctuations in patients with advanced levodopa-responsive Parkinson’s disease who do not have satisfactory… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
